Statistics from Altmetric.com
What is the evidence on the comparative effectiveness and safety of the antipsychotics for children and young adults with psychiatric and behavioural conditions?
Efficacy outcomes (disorder specific and non-specific symptoms; health-related quality of life; legal involvement; medication adherence; patient, parent- or care provider-reported outcomes; suicide-related behaviour); adverse events (dyslipidaemia, extrapyramidal symptoms, insulin resistance, prolactin-related and sexual side effects, sedation, weight and body composition).
Systematic review and meta analysis.
MEDLINE, Embase, CENTRAL, PsycINFO, IPA, CINAHL, Scopus, ProQuest Dissertations International, MedEffect Canada and TOXLINE, were searched from 1987 to February 2011. In addition, the authors hand searched clinical trial registers, reference lists of relevant reviews, proceedings from scientific meetings and Food and Drug Administration (FDA) reports and contacted drug manufacturers for published and unpublished study data.
Study selection and analysis
Controlled clinical trials (randomised and non-randomised) or cohort studies (prospective or retrospective) assessing FDA-approved antipsychotics in children and young people were included. Population: aged ≤24 years with one or more psychiatric and behavioural conditions (pervasive developmental disorder (PDD), disruptive behaviour disorder (DBD), bipolar disorder, schizophrenia or related psychosis, Tourette syndrome, …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.